Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0009443 (
cold
)
92,137
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
As a result of serial passages (42 passages) at low temperatures (26 degrees--28 degrees C) of two
influenza
H1N1 and H3N2 virus strains stable
cold
-adapted (ca) variants were produced. Investigations of them showed the ca A/USSR/03/84 (H1N1) variant to have ts-mutations in genes 1, 2, 4, 5, 7, and 8 and the ca A/USSR/215/79 (H3N2) to have ts-mutations in genes 1, 3, 4, 5, 7 and 8. These ca-variants may be recommended as attenuation donors to be used in recombination experiments with epidemic
influenza
viruses in order to obtain attenuated reassortant candidate vaccine strains.
...
PMID:[The selection of cold-adapted variants of the influenza viruses H1N1 and H3N2 and their antigenic and genetic characteristics]. 188 17
An analysis of ts-mutations in the genomes of native and
cold
-adapted variants of
influenza
A/Leningrad/134/57 (H2N2) virus based on the use of fowl plague virus ts mutants was carried out. The recombination test was done by the conventional method in chick embryo fibroblast culture (genes PB2, PB1, PA, NP, NA, M and NS) or cell systems permissive for reproduction of human
influenza
virus (gene HA). The
cold
-adapted strain A/Len/17 used for preparation of live
influenza
vaccine (LIV) for adults was shown to have 4 ts mutations: three in "internal" genes (PB2, NP, and M) and one in gene 4 coding for hemagglutinin (HA). The more attenuated
cold
-adapted donor A/Len/47 for preparation of similar LIV for children acquired three additional ts mutations: two (PB1 and NS) in "internal" genes and one in gene 6 coding for neuraminidase (NA). The accumulation of ts mutations in the genome of
cold
-adapter strains was found to be accompanied by a decrease in their pneumotropicity for mice as well as their detectability in different organs of these animals.
...
PMID:[Mutations in the genes coding for hemagglutinin and neuraminidase in cold-adapted variants of the influenza virus A/Leningrad/134/57 (H2N2)]. 188 32
The attenuated
cold
-adapted strain of
influenza
A virus that is a candidate live-virus vaccine suppressed clinical disease in ferrets when given simultaneously with a virulent epidemic strain of
influenza
A virus. The
cold
-adapted virus effectively prevented disease, even when the epidemic strain was of a different subtype than the attenuated virus. In this case, ferrets given a mixed inoculum produced antibody to both subtypes in the absence of clinical disease, indicating that both viruses are replicating in the respiratory tract. These findings suggest the possibility of the development of a novel class of antivirals for
influenza
, namely a live virus that is a dominant-negative attenuated mutant that interferes with the replication of epidemic strains of virus.
...
PMID:Dominant-negative mutants as antiviral agents: simultaneous infection with the cold-adapted live-virus vaccine for influenza A protects ferrets from disease produced by wild-type influenza A. 195 19
To study the risk of anencephaly related to
common cold
during pregnancy, a case-control study was made. The series comprised 393 Finnish mothers of anencephalic children and their time-area-matched controls in the period 1964 through 1982. Seventy mothers of anencephalic infants and 17 controls had reported
common cold
in the first trimester [adjusted odds ratio 4.5; 95% confidence interval (2.2-9.1)]. Reported
common cold
in the second trimester was not associated with anencephaly. As suggested by our previous cohort study in the same population, a true viral
influenza
resembling "common cold" might not explain the observed association.
...
PMID:Anencephaly and maternal common cold. 195 63
Minor illnesses, such as colds and
influenza
, are frequent, widespread and a major cause of absenteeism from work and education. Yet the clinical symptoms of such illnesses may not be so great as to stop people from working or from carrying out everyday activities. It is therefore important to determine whether these viral infections alter central nervous system function and change performance efficiency. Data on this topic are almost non-existent, which in part reflects the difficulties inherent in carrying out such studies. In real life it is almost impossible to predict when such illnesses will occur, and difficult to establish which virus produced the illness. This problem was overcome by studying experimentally induced infections and illnesses at the Medical Research Centre (MRC)
Common Cold
Unit in Salisbury. Results from this research programme show that: (i) colds and
influenza
have selective effects on performance; (ii) even sub-clinical infections can produce performance impairments; (iii) performance may be impaired during the incubation period of the illness; (iv) performance impairments may still be observed after the clinical symptoms have gone. These results have strong implications for occupational safety and efficiency and it is now essential to assess the impact of naturally occurring colds and
influenza
on real-life activities.
...
PMID:Respiratory virus infections and performance. 197 Aug 98
Specific immunity to
influenza
is associated with a systemic immune response (serum haemagglutination inhibition antibody), local respiratory immune response (virus-specific local IgA and IgG antibodies in nasal wash), and with the cell-mediated immune response. Both inactivated and live
influenza
vaccines induce virus-specific serum antibody which can protect against infection with
influenza
virus possessing the same antigenic specificity. In the absence of serum antibodies, local antibodies in nasal wash are a major determinant of resistance to infection with
influenza
virus. In comparative studies in humans it was shown that nasal secretory IgA develops chiefly after immunization with live
cold
-adapted (CA) vaccine, but persistent nasal secretory IgG was detected in both CA live and inactivated vaccines. The origin of nasal wash haemagglutination inhibition (HI) antibodies is not completely known. Recently it was found that cytotoxic T-cells (CTL) play an important role in immunity against
influenza
and in clearance of
influenza
virus from the body. In primed humans, inactivated
influenza
vaccine stimulates a cross-reactive T-cell response, whereas the ability of inactivated vaccine to stimulate such immunity in unprimed humans has not been determined. Data on the T-cell response to live vaccine in humans are limited to the development of secondary T-cell responses in primed individuals vaccinated with a host-range (HR) attenuated vaccine. The data obtained have shown that immunity induced by inactivated
influenza
vaccines is presumably dependent on the stimulation of serum antibody. Live CA vaccines not only stimulate a durable serum antibody response, but also induce long-lasting local respiratory tract IgA antibody that plays an important role in host protection.
...
PMID:The immune response to influenza vaccines. 198 Apr 1
Segment 7 (M) of the
cold
-adapted live
influenza
A virus vaccine plays a primary role in the ability of this virus to interfere with the replication of wild-type
influenza
A viruses. This conclusion is based on several lines of evidence. Single gene reassortant viruses derived by crossing
influenza
A/Ann Arbor/6/60 (H2N2)
cold
-adapted donor virus with an epidemic wild-type strain, A/Korea/1/82 (H3N2), were tested for their ability to interfere with wild-type parental virus in the Madin-Darby line of canine kidney cells and embryonated eggs. It was apparent in both hosts that the single gene reassortant carrying segment 7 (M) derived from the
cold
-adapted virus was dominant over wild-type virus. Additional confirmation of the role of segment 7 (M) in trans-dominance of the
cold
-adapted vaccine virus was derived from the analysis of reassortants produced by mixed infection by a wild-type virus and its
cold
-adapted reassortant vaccine strain. After three serial passages, the virus yield contained a high proportion of reassortants carrying segment 7 (M) of the
cold
-adapted parental strain. When used in mixed infections, these reassortants were dominant over the replication of the parental wild-type virus.
...
PMID:The genes associated with trans-dominance of the influenza A cold-adapted live virus vaccine. 198 70
A
cold
-adapted (ca)
influenza
B reassortant vaccine consisting of two genes encoding the hemagglutinin and neuraminidase from wild-type
influenza
B/Ann Arbor/1/86 virus and the six internal RNA segments from
influenza
B/Ann Arbor/1/66 ca virus was evaluated in 18 seropositive and 57 seronegative infants and children. The ca reassortant was infectious in seronegative vaccinees, with an estimated 50% human infectious dose of 10(2.5) TCID50. Nasal wash specimens from vaccinees retained the temperature-sensitive phenotype, indicating that the virus was phenotypically stable after replication in fully susceptible children. The vaccine was highly immunogenic in the seronegative vaccinees; 54% of the seropositive vaccinees also developed an increase in serum antibody. The ca vaccine was well tolerated, with only a mild increase in upper respiratory tract symptoms seen in the seronegative vaccinees. These studies indicate that the B/Ann Arbor/1/86 ca reassortant is safe, immunogenic, and phenotypically stable in infants and children.
...
PMID:Safety and immunogenicity of live attenuated cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in infants and children. 201 Jun 27
Characteristics of avian-human (ah) and
cold
-adapted (ca)
influenza
A/Kawasaki/9/86 (H1N1) reassortant vaccine viruses were compared in 37 seronegative adults and 122 seronegative infants and children. The 50% human infectious dose (HID50) in infants and children was 10(2.9) and 10(2.6) TCID50 for the ah and ca vaccine, respectively. The ah
influenza
A/Kawasaki/9/86 reassortant was reactogenic: 24% of infants and children infected with greater than or equal to 100 HID50 had fever greater than or equal to 39.4 degrees C. Since H3N2 ah vaccines were previously shown to be adequately attenuated, it is reasonable to suggest that the genes that code for hemagglutinin and neuraminidase of the H1N1 virus apparently influence the reactogenicity of reassortant viruses derived from the avian influenza A/Mallard/New York/6750/78 donor virus. Because this avian virus does not reproducibly confer a satisfactory level of attenuation to each subtype of
influenza
A virus, it is not a suitable donor virus for attenuation of wild-type
influenza
viruses. In contrast, the ca A/Ann Arbor/6/60 donor virus reliably confers attenuation characteristics to a variety of H1N1 and H3N2
influenza
A viruses.
...
PMID:The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children. 201 51
To question whether cellular immunity was stimulated by live-attenuated viruses in older, chronically ill adults, we intranasally inoculated 2 groups of volunteers (n = 37) with 2 different
cold
-recombinant, live-attenuated
influenza
A virus vaccines, and measured peripheral blood mononuclear cell responsiveness to
influenza
antigens and mitogen before and after vaccination. Lymphocyte proliferation to vaccine virus and to heterosubtypic
influenza
A virus increased postvaccination even in the subpopulation of vaccines who had a 4-fold nasal wash antibody titer rise to vaccine virus hemagglutinin, but no concomitant serum antibody titer rise to hemagglutinin. Vaccines aged greater than or equal to 65 years exhibited a rise in proliferation to vaccine virus postvaccination, as well. Based on lymphocyte proliferation, vaccine virus infection induced an enhanced cell-mediated immune response. Higher prevaccination serum antibody titers, however, were associated with protection from vaccine virus infection, and higher lymphocyte proliferation was not.
...
PMID:Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live-attenuated viruses. 202 30
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>